Deals and Data

Deals and Data

Abbiotech founder gets training, assistance from Small Business Administration; secures bank loan (U-T San Diego, 3-17/14)

Merck grants Q-CROC $1.8 million in support of research into personalized medicine approaches for cancer. (GenomeWeb, 04/04/14)

Lumena Pharmaceuticals files IPO; receives orphan drug designation for four liver diseases that have the common underlying cause of high bile acid levels. (U-T San Diego, 04/05/14)

Pfizer’s experimental breast cancer drug nearly doubles amount of time patients live without their disease getting worse. (Reuters, 04/06/14)

Vital Therapies lowers proposed deal size for upcoming IPO; develops bio-artificial liver cells for treatment of acute liver failure. (Renaissance Capital, 04/07/14)

Novartis’ meningitis B vaccine, Bexsero, gets breakthrough therapy status. (Reuters, 04/07/14)

Ellipse Technologies’ MAGEC Spinal Bracing and Distraction System successfully implanted in progressive spinal deformity patient. (Becker’s, 04/08/14)

Eli Lilly preps Phase III study for breast cancer drug, LY2835219, which shows early-stage promise. (Fierce Biotech, 04/08/14)

Monsanto study finds quick degradation of dsRNA in soil; the data also provides insights that can be used to evaluate future RNAi-incorporating agricultural products. (GenomeWeb, 04/08/14)

BioTheranostics collaborates with Prime Health Services for coverage of their tests for breast cancer and metastatic disease. (GenomeWeb, 04/09/14)

GlaxoSmithKline teams up with University of Texas in research alliance that aims to speed up development of cancer immunotherapies. (GEN News, 04/09/14)

Senomyx and PepsiCo collaborate to find new flavors that would restore a salty taste to low-sodium foods. (U-T San Diego, 04/09/14)

Celladon Gets FDA’s “Breakthrough Therapy” Status for Gene Therapy (Xconomy, 4/10/14)

U-T San Diego Q&A with Kim Kamdar of Domain Associates (U-T San Diego, 4/13/14)

Sequenom Claims Favorable USPTO Decisions on NIPT Patents (GenomeWeb, 4/14/14)

Thermo Fisher Scientific and the National University of Singapore today announced the signing of a memorandum of understanding to develop a strategic alliance to increase advance basic and applied research in Singapore. (GenomeWeb, 4/14/14)

Merck & Co said the U.S. Food and Drug Administration approved its grass pollen allergy drug Grastek, becoming the second such immunotherapy treatment to be given the go-ahead in recent weeks. (Reuters, 4/14/14)

Scripps Unveils New Drug Development Arm, Signs J&J as First Partner (Xconomy, 4/14/14)

The U.S. Food and Drug Administration approved GlaxoSmithKline Plc's Tanzeum injection for treating adults with type 2 diabetes, in combination with diet and exercise. (Reuters, 4/15/14)

Boehringer Ingelheim announced plans for more than 10 new launches of drugs in eight disease indications by 2016. The eight indications are diabetes, COPD, asthma, lung cancer, idiopathic pulmonary fibrosis (IPF), a rare form of leukaemia (AML), and the treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE). (GEN News, 4/16/14)

Top stem cell scientist joins Stemedica (U-T San Diego, 4/16/14)

« Return to Table of Contents